A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 752-758

  Francis, Sebastian ^a   Lucas, Claire ^a   Lane, Steven ^a   Wang, Lihui ^a   Watmough, Sarah ^a   Knight, Katy ^a   Bell, Jo ^a   Kaleel Rahman, Mohammed ^b   Lee, Edwin ^c   O'Brien, David ^d   Butt, Nauman M ^e   Sadik, Walid ^f   De Soysa, Lally ^g   Seale, Jim R C ^h   Salim, Rahuman ^a   Clark, Richard E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b WARRINGTON HOSPITAL   (United Kingdom)

^c Countess of Chester Hospital ^*  (United Kingdom)

^d SOUTHPORT AND ORMSKIRK HOSPITAL NHS TRUST   (United Kingdom)

^e ARROWE PARK HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^g WREXHAM MAELOR HOSPITAL   (United Kingdom)

^h YSBYTY GWYNEDD   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Dasatinib; Nilotinib; Tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; THIAZOLES; YOUNG ADULT;

EID: 84878490313     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.003     Document Type: Article

References (11)

1. O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., Radich J.P., et al. International Randomized study of Interferon versus STI571 (IRIS) 7 year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008, 112(11):76. [abstract].
2. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
3. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
4. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
5. Hochhaus A., Müller M.C., Radich J., Branford S., Kantarjian H.M., Hanfstein B., et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009, 23:1628-1633.
6. Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
7. Lucas C.M., Wang L., Austin G.M., Knight K., Watmough S.J., Shwe K.M., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
8. Saglio G., Kim D-W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. ENESTnd: a randomized comparison of nilotinib and imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
9. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
10. Wang L., Pearson K., Pillitteri L., Ferguson J.E., Clark R.E. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002, 118:771-777.
11. Gallipoli P., Shepherd P., Irvine D., Drummond M., Holyoake T. Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. Br J Haematol 2011, 155:128-130.